Product logins

Find logins to all Clarivate products below.


Interventional Oncology Devices | Market Insights | Europe (Supplemental) | 2025

The European interventional oncology device market will see modest growth through 2033, driven by increasing incidence and prevalence rates of cancer, cost-effectiveness of ablation and embolization devices compared to surgery, improved reimbursement, changing guidelines, launch of innovative products, increasing popularity of minimally invasive surgeries, and growing physician acceptance of interventional oncology procedures. However, growth in this market will be hindered by mixed clinical data, increasing-price competition, and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in Europe from 2019 to 2033.

Related Medtech Insights Reports

Report
Pain Management Devices – Market Insights – United States
The US pain management device market is driven by continuous product innovation aimed at enhancing treatment efficacy and addressing new indications. Favorable clinical evidence and pain management…
Report
Neurostimulation Devices – Market Insights – United States
The US neurostimulation device market will be driven by strategic acquisitions, rapid adoption of novel technologies and increasing availability of advanced products, and new approvals and device…
Report
Laparoscopic Devices – Market Insights – Asia Pacific
The Asia Pacific laparoscopic device market will experience modest growth through 2034. Growth over the forecast period will be driven mainly by the continued uptake of innovative premium priced…
Report
Diabetes Care Devices – Market Insights – Asia Pacific
The Asia Pacific diabetes care device market is expected to experience moderate growth over the forecast period, driven by a rising diabetes population, untapped market opportunities, regulatory…
Report
Heart Valve Devices – Market Insights – United States
The US heart valve device market continues to be driven by the introduction of novel products and key approvals for new indications of existing products. In particular, recent approvals of…